Why TNDM Stock Fell 0.1% on Nov 18, 2026
as of Wednesday, 9:53 AM ET
The reason we found
Stifel upgrades Tandem Diabetes Care to Buy
Stifel’s upgrade from Hold to Buy and higher price target of $26 provide a bullish reassessment of Tandem Diabetes Care’s prospects. The improved analyst view plausibly attracted buyers and helps explain the stock’s 3.22% gain today.
analyst upgradehigh confidence
Sources 1
Our call
Buy moredated Nov 18, 2026
Tandem Diabetes Care fell 13% over the past five trading days, far more than other health care stocks (down 6.3%), but its report on Nov 5 beat profit forecasts by 63%. We'd stop buying if Tandem Diabetes Care's next report misses profit forecasts.
Other moves on Nov 18
- OKTA+12.1%Federal cyber threat warning lifts Okta and cybersecurity stocks
- BLSH+10.8%Bullish rallies after earnings beat and $300 million buyback
- ACIW−10.3%ACI Worldwide names interim CEO as shares fall sharply
- UNH−10.2%Proposed Medicare fraud rule pressures UnitedHealth shares
- AAOI−9.8%AAOI Slides on Fresh $550 Million Stock Offering
- CBRS−9.6%Fund Exit and Nvidia Competition Pressure Cerebras Shares